Tumor marker tests (CEA and CA19-9). Tumor marker tests look for higher-than-normal amounts of certain substances in the blood, urine, or tissues of people with ...SkiptoContentSearchMenuYouarehereHome>TypesofCancer>BileDuctCancer(Cholangiocarcinoma)>BileDuctCancer(Cholangiocarcinoma):DiagnosisRequestPermissionsBileDuctCancer(Cholangiocarcinoma):DiagnosisApprovedbytheCancer.NetEditorialBoard,06/2020ONTHISPAGE: Youwillfindalistofcommontests,procedures,andscansthatdoctorsusetofindthecauseofamedicalproblem.Usethemenutoseeotherpages.Doctorsusemanyteststofind,ordiagnose,cancer.Theyalsodoteststolearnifcancerhasspreadtoanotherpartofthebodyfromwhereitstarted.Ifthishappens,itiscalledmetastasis.Forexample,imagingtestscanshowifthecancerhasspread.Imagingtestsshowpicturesoftheinsideofthebody.Doctorsmayalsodoteststolearnwhichtreatmentscouldworkbest.Formosttypesofcancer,abiopsyistheonlysurewayforthedoctortoknowifanareaofthebodyhascancer.Inabiopsy,thedoctortakesasmallsampleoftissuefortestinginalaboratory.Ifabiopsyisnotpossible,thedoctormaysuggestotherteststhatwillhelpmakeadiagnosis.Thissectiondescribesoptionsfordiagnosingbileductcancer.Notalltestslistedbelowwillbeusedforeveryperson.Yourdoctormayconsiderthesefactorswhenchoosingadiagnostictest:ThetypeofcancersuspectedYoursignsandsymptomsYourageandgeneralhealthTheresultsofearliermedicaltestsInadditiontoaphysicalexamination,thefollowinglabtestsmaybeusedtodiagnosebileductcanceroridentifyitasthecauseofjaundice(seeSymptomsandSigns):Bloodchemistrytests. Bloodchemistrytestsmeasurethelevelsofbilirubinandalkalinephosphataseandcheckotherliverfunctions.Highlevelsofthesesubstancescouldindicatethatthebileductisnotworkingwell.Tumormarkertests(CEAandCA19-9).Tumormarkertests lookforhigher-than-normalamountsofcertainsubstancesintheblood,urine,ortissuesofpeoplewithcertaintypesofcancer.Bileductcancermaycausehighlevelsofcarcinoembryonicantigen(CEA)andCA19-9intheblood.However,apersoncanhavebileductcancereveniftherearenormallevelsofthesetumormarkers.Also,

At present, the term cholangiocarcinoma (CCA) includes all bile duct cancers, ... CA19-9 is a serum tumor marker for pancreatic cancer, ...HomeSubmitManuscriptMyAccountOncologyLettersJournalHomeCurrentIssueForthcomingIssueMostReadMostCited(Dimensions)PastTwoYearsTotalMostCited(CrossRef)PastYear0TotalSocialMediaPastMonthPastYearTotalArchiveInformationOnlineSubmissionInformationforAuthorsLanguageEditingInformationforReviewersEditorialPoliciesEditorialBoardJoinEditorialBoardAimsandScopeAbstractingandIndexingBibliographicInformationInformationforLibrariansInformationforAdvertisersReprintsandpermissionsContacttheEditorGeneralInformationAboutSpandidosConferencesJobOpportunitiesContactTermsandConditionsDiagnosticandprognosticserummarkerofcholangiocarcinoma(Review)Authors:XiaojunZengHualinTaoViewAffiliationsAffiliations:DepartmentofLaboratoryMedicine,LuzhouMedicalCollege,Luzhou,Sichuan646000,P.R.China,DepartmentofLaboratoryMedicine,AffiliatedHospitalofLuzhouMedicalCollege,Luzhou,Sichuan646000,P.R.ChinaPublishedonlineon:November10,2014   https://doi.org/10.3892/ol.2014.2696Pages:3-8Metrics:TotalViews:0(SpandidosPublications:|PMCStatistics:)Metrics:TotalPDFDownloads:0(SpandidosPublications:|PMCStatistics:)CitedBy(CrossRef):0citationsLoadingArticles...Thisarticleismentionedin:AbstractCholangiocarcinoma(CCA)isafataldiseasethatistypicallydiagnosedlateandtreatedineffectively.AsthemorbidityandmortalityratesforCCArisemarkedly,patietnswithCCAcurrentlyhaveapoorprognosis.However,ifitwerepossibletodiagnoseCCAearlywhileeffectivetreatmethodsareavailable,CCApatientswouldachieveabetterqualityoflife.Therefore,preventingtheprocessofCCAintheearlystagesisanurgentproblemtosolve.Anaccurate,quickandsafemethodtodiagnoseearly‑stageCCAisrequired.Thepresentreviewdiscussestheriskfactors,statusofresearchandcertainserummarkersofCCA.Thesensitivityandspecificityofthesemarkersdifferfromeachother.ToexplorethemoreaccurateserummarkersmaybeanoveldirectionandmethodforthediagnosisofCCAinlaboratorymedicineinthefu

We herein discuss the most promising markers for this tumor. Serum Markers. A list of currently available serum markers and those that are promising is provided ...SkiptoMainContentCookiesdisabledToolsBrowsesampleissueGetContentalertsSubscribetothisjournalCookiesaredisabledforthisbrowser.WileyOnlineLibraryrequirescookiesforauthenticationanduseofothersitefeatures;therefore,cookiesmustbeenabledtobrowsethesite.DetailedinformationonhowWileyusescookiescanbefoundinourPrivacyPolicy.JournallistmenuJournalArticlesActionsToolsFollowjournalNavigationBarMenuHomeHomeBrowseAcceptedArticlesEarlyViewCurrentIssueAllIssuesFollowjournalAlertTwitterchannelFacebookpageRSSchannelAASLDMemberLoginAASLDMemberLoginLogintoWileyOnlineLibraryEmailorCustomerIDPasswordForgotpassword?NEWUSER>INSTITUTIONALLOGIN>ChangePasswordOldPasswordNewPasswordTooShortWeakMediumStrongVeryStrongTooLongPasswordChangedSuccessfullyYourpasswordhasbeenchangedCreateanewaccountEmailorCustomerIDReturninguserForgotyourpassword?Enteryouremailaddressbelow.EmailorCustomerIDPleasecheckyouremailforinstructionsonresettingyourpassword.Ifyoudonotreceiveanemailwithin10minutes,youremailaddressmaynotberegistered,andyoumayneedtocreateanewWileyOnlineLibraryaccount.RequestUsernameCan'tsignin?Forgotyourusername?EnteryouremailaddressbelowandwewillsendyouyourusernameEmailorCustomerIDCloseIftheaddressmatchesanexistingaccountyouwillreceiveanemailwithinstructionstoretrieveyourusername

The tumor marker carbohydrate antigen 19-9 (CA 19-9) can be evaluated in pancreatic and bile duct malignancies, as well as in benign cholestasis. A serum CA 19- ...ForYouNews&PerspectiveDrugs&DiseasesCME&EducationAcademyVideoDecisionPointSpecialty:MultispecialtyAllergy&ImmunologyAnesthesiologyBusinessofMedicineCardiologyCriticalCareDermatologyDiabetes&EndocrinologyEmergencyMedicineFamilyMedicineGastroenterologyGeneralSurgeryHematology-OncologyHIV/AIDSHospitalMedicineInfectiousDiseasesInternalMedicineMultispecialtyNephrologyNeurologyOb/Gyn&Women'sHealthOncologyOphthalmologyOrthopedicsPathology&LabMedicinePediatricsPlasticSurgeryPsychiatryPublicHealthPulmonaryMedicineRadiologyRheumatologyTransplantationUrologyMedicalStudentsNursesPharmacistsResidentsTodayonMedscapeEdition:ENGLISHDEUTSCHESPAÑOLFRANÇAISPORTUGUÊSLogInSignUpIt'sFree!Edition:ENGLISHDEUTSCHESPAÑOLFRANÇAISPORTUGUÊSRegisterLogInNoResultsNoResultsMonday,August16,2021ForYouNews&PerspectiveDrugs&DiseasesCME&EducationAcademyVideoDecisionPointclosePleaseconfirmthatyouwouldliketologoutofMedscape.Ifyoulogout,youwillberequiredtoenteryourusernameandpasswordthenexttimeyouvisit.LogoutCancelhttps://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cDovL3d3dy5tZWRzY2FwZS5jb20vYW5zd2Vycy8yNzczOTMtOTM2NzAvd2hhdC1pcy10aGUtcm9sZS1vZi10dW1vci1tYXJrZXJzLWluLXRoZS1kaWFnbm9zaXMtb2YtY2hvbGFuZ2lvY2FyY2lub21hLWNjYw==processing....Drugs&Diseases>Oncology>CholangiocarcinomaQ&AWhatistheroleoftumormarkersinthediagnosisofcholangiocarcinoma(CCC)?Updated:Dec28,2019Author:PeterEDarwin,MD;ChiefEditor:NJosephEspat,MD,MS,FACS more...ReferencesShareEmailPrintFeedbackCloseFacebookTwitterLinkedInGoogle+AnswerAvarietyofmarkershavebeentestedinbileandserum,withlimitedsuccess.Thisbecomesasignificantissueinprimarysclerosingcholangitis(PSC),whoseclinicalfeaturesandimagingfindingsoverlapwiththoseofcholangiocarcinoma.Thetumormarkercarbohydrateantigen19-9(CA19-9)canbeevaluatedinpancreaticandbileductmalignancies,aswe

CEA is a commonly used tumor marker and belongs to clinical routine for patients with suspected gastrointestinal malignancies. It has been suggested that CEA ...NCBISkiptomaincontentSkiptonavigationResourcesHowToAboutNCBIAccesskeysMyNCBISignintoNCBISignOutTryoutPMCLabsandtelluswhatyouthink.LearnMore.JournalListEurJMedResv.15(8);2010PMC3458701EurJMedRes.2010;15(8):357–361.Publishedonline2010Aug20.doi: 10.1186/2047-783X-15-8-357PMCID:PMC3458701PMID:20947473TumormarkersasadiagnostickeyforhilarcholangiocarcinomaBJuntermanns,1SRadunz,1MHeuer,1SHertel,2HReis,3JPNeuhaus,1SVernadakis,1TTrarbach,4APaul,1andGMKaiser1BJuntermanns1DepartmentofGeneral,VisceralandTransplantationSurgery,UniversityHospitalofEssen,GermanyFindarticlesbyBJuntermannsSRadunz1DepartmentofGeneral,VisceralandTransplantationSurgery,UniversityHospitalofEssen,GermanyFindarticlesbySRadunzMHeuer1DepartmentofGeneral,VisceralandTransplantationSurgery,UniversityHospitalofEssen,GermanyFindarticlesbyMHeuerSHertel2InstituteforMedicalInformatics,BiometryandEpidemiology,UniversityHospitalofEssen,GermanyFindarticlesbySHertelHReis3InstituteofPathologyandNeuropathology,UniversityHospitalofEssen,GermanyFindarticlesbyHReisJPNeuhaus1DepartmentofGeneral,VisceralandTransplantationSurgery,UniversityHospitalofEssen,GermanyFindarticlesbyJPNeuhausSVernadakis1DepartmentofGeneral,VisceralandTransplantationSurgery,UniversityHospitalofEssen,GermanyFindarticlesbySVernadakisTTrarbach4DepartmentofMedicine,WestGermanCancerCentre,UniversityHospitalofEssen,GermanyFindarticlesbyTTrarbachAPaul1DepartmentofGeneral,VisceralandTransplantationSurgery,UniversityHospitalofEssen,GermanyFindarticlesbyAPaulGMKaiser1DepartmentofGeneral,VisceralandTransplantationSurgery,UniversityHospitalofEssen,GermanyFindarticlesbyGMKaiserAuthorinformationArticlenotesCopyrightandLicenseinformationDisclaimer1DepartmentofGeneral,VisceralandTransplantationSurgery,UniversityHospitalofEssen,Germany2InstituteforMedicalInformatics,BiometryandEpidemiology,UniversityHospitalof

Clipboard,SearchHistory,andseveralotheradvancedfeaturesaretemporarilyunavailable.SkiptomainpagecontentCOVID-19InformationPublichealthinformation(CDC)Researchinformation(NIH)SARS-CoV-2data(NCBI)Preventionandtreatmentinformation(HHS)Español AccesskeysNCBIHomepageMyNCBIHomepageMainContentMainNavigationSearch:SearchAdvancedClipboardUserGuideSaveEmailSendtoClipboardMyBibliographyCollectionsCitationmanagerDisplayoptionsDisplayoptionsFormatAbstractPubMedPMIDSavecitationtofileFormat:Summary(text)PubMedPMIDAbstract(text)CSVCreatefileCancelEmailcitationSubject:1selecteditem:8554130-PubMedTo:Format:SummarySummary(text)AbstractAbstract(text)MeSHandotherdataSendemailCancelAddtoCollectionsCreateanewcollectionAddtoanexistingcollectionNameyourcollection:Namemustbelessthan100charactersChooseacollection:UnabletoloadyourcollectionduetoanerrorPleasetryagainAddCancelAddtoMyBibliographyMyBibliographyUnabletoloadyourdelegatesduetoanerrorPleasetryagainAddCancelYoursavedsearchNameofsavedsearch:Searchterms:TestsearchtermsWouldyoulikeemailupdatesofnewsearchresults?SavedSearchAlertRadioButtonsYesNoEmail:(change)Frequency:MonthlyWeeklyDailyWhichday?ThefirstSundayThefirstMondayThefirstTuesdayThefirstWednesdayThefirstThursdayThefirstFridayThefirstSaturdayThefirstdayThefirstweekdayWhichday?SundayMondayTuesdayWednesdayThursdayFridaySaturdayReportformat:SummarySummary(text)AbstractAbstract(text)PubMedSendatmost:1item5items10items20items50items100items200itemsSendevenwhentherearen'tanynewresultsOptionaltextinemail:SaveCancelCreateafileforexternalcitationmanagementsoftwareCreatefileCancelYourRSSFeedNameofRSSFeed:Numberofitemsdisplayed:510152050100CreateRSSCancelRSSLinkCopyFulltextlinksElsevierScienceFulltextlinksActionsCiteFavoritesDisplayoptionsDisplayoptionsFormatAbstractPubMedPMIDSharePermalinkCopyPagenavigationTitle&authorsAbstractSimilararticlesCitedbyPublicationtypesMeSHtermsSubstancesRelatedinformationGrantsupportLinkOut-moreresourcesTitle&authorsAbstractSimilararticlesCitedbyPublicationtypesMe

ForYouNews&PerspectiveDrugs&DiseasesCME&EducationAcademyVideoDecisionPointEdition:ENGLISHDEUTSCHESPAÑOLFRANÇAISPORTUGUÊSLogInSignUpIt'sFree!Edition:ENGLISHDEUTSCHESPAÑOLFRANÇAISPORTUGUÊSRegisterLogInNoResultsNoResultsForYouNews&PerspectiveDrugs&DiseasesCME&EducationAcademyVideoDecisionPointclosePleaseconfirmthatyouwouldliketologoutofMedscape.Ifyoulogout,youwillberequiredtoenteryourusernameandpasswordthenexttimeyouvisit.LogoutCancelhttps://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cDovL2VtZWRpY2luZS5tZWRzY2FwZS5jb20vYXJ0aWNsZS8yNzczOTMtd29ya3Vwprocessing....Drugs&Diseases>OncologyCholangiocarcinoma WorkupUpdated:Apr20,2020Author:PeterEDarwin,MD;ChiefEditor:NJosephEspat,MD,MS,FACS more...ShareEmailPrintFeedbackCloseFacebookTwitterLinkedInGoogle+SectionsCholangiocarcinomaSectionsCholangiocarcinomaOverviewPracticeEssentialsPathophysiologyEpidemiologyShowAllPresentationHistoryPhysicalCausesShowAllDDxWorkupLaboratoryStudiesImagingStudiesProceduresHistologicFindingsStagingAngiographyShowAllTreatmentApproachConsiderationsStentPlacementPhotodynamicTherapyRadiationTherapyPharmacotherapySurgicalCareConsultationsShowAllGuidelinesMedicationMedicationSummaryFGFRInhibitorsShowAllFollow-upFurtherOutpatientCareComplicationsPrognosisShowAllQuestions&AnswersMediaGalleryTablesReferencesWorkupLaboratoryStudiesRoutinelabstudiesExtrahepaticcholestasisisreflectedinelevatedconjugated(ie,direct)bilirubinlevels.Alkalinephosphataselevelsusuallyriseinconjunctionwithbilirubinlevels.Becausealkalinephosphataseisofbiliaryorigin,gamma-glutamyltransferase(GGT)alsowillbeelevated.Levelsofaminotransferases(ie,aspartateaminotransferase[AST],alanineaminotransferase[ALT])maybenormalorminimallyelevated.Biochemicaltestsofhepaticfunction(ie,albumin,prothrombintime[PT])arenormalinearlydisease.Withprolongedobstruction,theprothrombintime(PT)canbecomeelevatedbecauseofvitaminKmalabsorption.Hypercalcemiamayoccuroccasionallyintheabsenceofosteolyticmetastasis.Tumormarker

Treatment · Surgery. When possible, doctors try to remove as much of the cancer as they can. · Liver transplant. · Chemotherapy. · Radiation therapy ...COVID-19:Advice,updatesandvaccineoptionsWeareopenforsafein-personcare.Learnmore:MayoClinicfactsaboutcoronavirusdisease2019(COVID-19)OurCOVID-19patientandvisitorguidelines,plustrustedhealthinformationLateston COVID-19vaccination bysite:ArizonapatientvaccinationupdatesArizona,FloridapatientvaccinationupdatesFlorida,RochesterpatientvaccinationupdatesRochesterandMayoClinicHealthSystempatientvaccinationupdatesMCHSSkiptositenavigationSkiptoContentThiscontentdoesnothaveanEnglishversion.ThiscontentdoesnothaveanArabicversion.SectionsforCholangiocarcinoma(bileductcancer)Symptoms&causesDiagnosis&treatmentDoctors&departmentsCareatMayoClinicPrintDiagnosisEndoscopicretrogradecholangiopancreatographyOpenpop-updialogboxCloseEndoscopicretrogradecholangiopancreatographyEndoscopicretrogradecholangiopancreatographyEndoscopicretrogradecholangiopancreatography(ERCP)usesadyetohighlightthebileductsonX-rayimages.Athin,flexibletube(endoscope)withacameraontheendispasseddownyourthroatandintoyoursmallintestine.Thedyeenterstheductsthroughasmallhollowtube(catheter)passedthroughtheendoscope.EndoscopicultrasoundOpenpop-updialogboxCloseEndoscopicultrasoundEndoscopicultrasoundDuringanendoscopicultrasound,yourdoctorinsertsalong,flexibletube(endoscope)downyourthroatandintoyourabdomen.Anultrasounddeviceattheendofthetubeemitssoundwavesthatgenerateimagesofnearbytissues.Ifyourdoctorsuspectscholangiocarcinoma,heorshemayhaveyouundergooneormoreofthefollowingtests:Liverfunctiontests.Bloodteststomeasureyourliverfunctioncangiveyourdoctorcluesaboutwhat'scausingyoursignsandsymptoms.Tumormarkertest.Checkingthelevelofcancerantigen(CA)19-9inyourbloodmaygiveyourdoctoradditionalcluesaboutyourdiagnosis.CA19-9isaproteinthat'soverproducedbybileductcancercells.AhighlevelofCA19-9inyourblooddoesn'tmeanyouhavebileductcancer,though.Thisresultcanalsooccurinotherbileductdiseases,

Carcinoembryonic antigen (CEA), a well-established tumor marker particularly in the field of colorectal and other adenocarcinomas, has gained ...SkiptomaincontentThankyouforvisitingnature.com.YouareusingabrowserversionwithlimitedsupportforCSS.Toobtainthebestexperience,werecommendyouuseamoreuptodatebrowser(orturnoffcompatibilitymodeinInternetExplorer).Inthemeantime,toensurecontinuedsupport,wearedisplayingthesitewithoutstylesandJavaScript.AdvertisementnaturescientificreportsarticlesarticleCEAbutnotCA19-9isanindependentprognosticfactorinpatientsundergoingresectionofcholangiocarcinomaDownloadPDFSubjectsBileductcancerPrognosticmarkersAbstractCholangiocarcinoma(CCA)representsarareformofprimarylivercancerwithincreasingincidencebutdismalprognosis.Surgicaltreatmenthasremainedtheonlypotentiallycurativetreatmentoption,butitremainsunclearwhichpatientsbenefitmostfromliversurgery,highlightingtheneedfornewpreoperativestratificationstrategies.Inclinicalroutine,CA19-9representsthemostwidelyusedtumormarkerinCCApatients.However,dataontheprognosticvalueofCA19-9inCCApatientsarelimitedandofteninconclusive,mostlyduetosmallcohortsizes.Here,weinvestigatedtheprognosticvalueofCA19-9incomparisonwithotherstandardlaboratorymarkersinalargecohortofCCApatientsthatunderwenttumorresection.Ofnote,whileCA19-9andCEAwereabletodiscriminatebetweenCCAandhealthycontrols,CEAshowedahigheraccuracyforthedifferentiationbetweenCCAandpatientswithprimarysclerosingcholangitis(PSC)comparedtoCA19-9.Furthermore,patientswithelevatedlevelsofC-reactiveprotein(CRP),CA19-9orCEAshowedasignificantlyimpairedsurvivalinKaplan-Meiercurveanalysis,butsurprisingly,onlyCEAbutnotCA19-9representedanindependentpredictorofsurvivalinmultivariateCox-regressionanalysis.OurdatasuggestthatCEAmighthelptoidentifyCCApatientswithanunfavourableprognosisaftertumorresection.DownloadPDFIntroductionAlthoughcholangiocarcinoma(CCA)representsthesecondmostcommonprimaryhepaticmalignancy,itcanbeconsideredararetypeofgastrointestinalcancercomprisinglessthan1%o

CloseOpenShareonFacebookTwitterGoogle+Email Notice:Usersmaybeexperiencingissueswithdisplayingsomepagesonstanfordhealthcare.org.Weareworkingcloselywithourtechnicalteamstoresolvetheissueasquicklyaspossible.Thankyouforyourpatience. COVID-19Updates:    COVID-19Resources »    VaccineUpdate»    UpdatedVisitorPolicy »     WhatWe'reDoingtoKeepYouSafe »MenuSearchMenuSearchDoctors,Clinics&Locations,Conditions&TreatmentsPatients&VisitorsMyHealthBillingInsuranceMedicalRecordsSupportGroupsFinancialAssistanceCOVID-19ResourceCenterLocationsandParkingVisitorPolicyHospitalCheck-inInternationalPatientsContactUsViewAllInformationforPatients&Visitors»Weareavailabletoassistyou24/7.650-498-3333GuestServices@stanfordhealthcare.orgViewthechangestoourvisitorpolicy » ViewinformationforGuestServices»NewtoMyHealth?ManageYourCareFromAnywhere.AccessyourhealthinformationfromanydevicewithMyHealth. Youcanmessageyourclinic,viewlabresults,scheduleanappointment,andpayyourbill.ALREADYHAVEANACCESSCODE?ActivateAccountDON'THAVEANACCESSCODE?CreateaNewAccountNEEDMOREDETAILS?LearnMoreaboutMyHealth»MyHealthforMobileGettheiPhoneMyHealthapp»GettheAndroidMyHealthapp»WELCOMEBACKForgotUsernameorPassword?NeedHelp?ClearTypesofTumorMarkersAboutAboutOverviewTypesProstate-specificantigen(PSA)Prostaticacidphosphatase(PAP)CA125Carcinoembryonicantigen(CEA)Alpha-fetoprotein(AFP)Humanchorionicgonadotropin(HCG)CA19-9CA15-3CA27-29Lactatedehydrogenase(LDH)Neuron-specificenolase(NSE)BladdertumormarkerstudiesOverviewTypesProstate-specificantigen(PSA)Prostaticacidphosphatase(PAP)CA125Carcinoembryonicantigen(CEA)Alpha-fetoprotein(AFP)Humanchorionicgonadotropin(HCG)CA19-9CA15-3CA27-29Lactatedehydrogenase(LDH)Neuron-specificenolase(NSE)BladdertumormarkerstudiesTypesofTumorMarkersSomeofthemoreusefultumormarkersinclude:Prostate-specificantigen(PSA)Prostaticacidphosphatase(PAP)CA125Carcinoembryonicantigen(CEA)Alpha-fetoprotein(AFP)Humanchorionicgonadotropin(HCG)CA19-9CA15-3CA27-29Lactatedehydrogenase(LDH)Neuron-specificenolase(NSE)

tion of the tumor markers carcinoembryonic antigen. (CEA) and carbohydrate antigen 19-9 (CA19-9) in the diagnosis of cholangiocarcinoma in patients with PSC ...ThissiterequiresCookiestobeenabledtofunction.PleaseensureCookiesareturnedonandthenre-visitthedesiredpage.

This review summarizes the principal characteristics of serum markers of cholangiocarcinoma. The tumour markers used frequently such as Carbohydrate antigen ...Clipboard,SearchHistory,andseveralotheradvancedfeaturesaretemporarilyunavailable.SkiptomainpagecontentCOVID-19InformationPublichealthinformation(CDC)Researchinformation(NIH)SARS-CoV-2data(NCBI)Preventionandtreatmentinformation(HHS)Español AccesskeysNCBIHomepageMyNCBIHomepageMainContentMainNavigationSearch:SearchAdvancedClipboardUserGuideSaveEmailSendtoClipboardMyBibliographyCollectionsCitationmanagerDisplayoptionsDisplayoptionsFormatAbstractPubMedPMIDSavecitationtofileFormat:Summary(text)PubMedPMIDAbstract(text)CSVCreatefileCancelEmailcitationSubject:1selecteditem:23396291-PubMedTo:Format:SummarySummary(text)AbstractAbstract(text)MeSHandotherdataSendemailCancelAddtoCollectionsCreateanewcollectionAddtoanexistingcollectionNameyourcollection:Namemustbelessthan100charactersChooseacollection:UnabletoloadyourcollectionduetoanerrorPleasetryagainAddCancelAddtoMyBibliographyMyBibliographyUnabletoloadyourdelegatesduetoanerrorPleasetryagainAddCancelYoursavedsearchNameofsavedsearch:Searchterms:TestsearchtermsWouldyoulikeemailupdatesofnewsearchresults?SavedSearchAlertRadioButtonsYesNoEmail:(change)Frequency:MonthlyWeeklyDailyWhichday?ThefirstSundayThefirstMondayThefirstTuesdayThefirstWednesdayThefirstThursdayThefirstFridayThefirstSaturdayThefirstdayThefirstweekdayWhichday?SundayMondayTuesdayWednesdayThursdayFridaySaturdayReportformat:SummarySummary(text)AbstractAbstract(text)PubMedSendatmost:1item5items10items20items50items100items200itemsSendevenwhentherearen'tanynewresultsOptionaltextinemail:SaveCancelCreateafileforexternalcitationmanagementsoftwareCreatefileCancelYourRSSFeedNameofRSSFeed:Numberofitemsdisplayed:510152050100CreateRSSCancelRSSLinkCopyFulltextlinksHindawiLimitedFreePMCarticleFulltextlinksActionsCiteFavoritesDisplayoptionsDisplayoptionsFormatAbstractPubMedPMIDSharePermalinkCopyPagenavigationTitle&authorsAbs

Followourblogforeducation,inspiration,andsupportduringtheCOVID-19pandemic.EspañolSignupforouremailTogglenavigationCancerTypesDiscoverinformationaboutdifferenttypesofcancerCancerTypesBoneCancersBrainTumorsBreastCancerCarcinoid&NeuroendocrineTumorsEndocrineSystemCancersGastrointestinalCancersGynecologicCancersHeadandNeckCancersLeukemiaLungCancersLymphomasMetastaticCancerMultipleMyelomaOncoLinkVetPediatricCancersPenileCancerPheochromocytomaProstateCancerSarcomasSkinCancersTesticularCancerThyroidCancerUrinaryTractCancersThymoma/ThymicCarcinomaPatientsLearnaboutcancer,diagnosis,treatment,coping&survivorshipCancerTreatmentGettingCancerTreatment?StartHere!BoneMarrowTransplantsCancerMedicationsClinicalTrialsComplementaryandAlternativeMedicineGeneTherapyHormoneTherapyHospitalHelpersImmunotherapyInterventionalSpecialtiesProcedures&DiagnosticTestsProtonTherapyRadiationSurgeryTargetedTherapiesVaccineTherapiesRiskandPreventionDiet,AlcoholandCancerEnvironmentalandOccupationalExposuresExercise,BodyWeightandCancerGenetics&FamilyHistoryMedications,HealthHistoryandCancerRiskPrevention&ScreeningSexualHistory&HumanPapillomavirus(HPV)Smoking,TobaccoandCancerReduceMyRiskToolSupportAdolescents&YoungAdults(AYA)CopingwithCOVIDCaregiversCopingWithCancerCreativeInspirationDistressScreeningResponseTools(DSRT)Exercise&CancerHospiceCare&PalliativeCareInsurance,Legal,Employment&FinancialConcernsManagingPractical&EmotionalConcernsNutritionandCancerOncoPilot:NavigatingtheCancerJourneySexuality&FertilitySideEffectsSurvivorshipCreateOncoLifeSurvivorshipCarePlanHealthcareProfessionalsFindresources&toolsforoncologyhealthcareprofessionalsHealthcareProfessionalsBuildMyPatientTreatmentBinderFindMyDrugToolOncolifeSurvivorshipCarePlanOncoLinkRxRegimenPrinterSmartALACCCarePlanClinicalTrialsDistressScreeningResponseTools(DSRT)O-Pro:PortalforOncologyProfessionalsOncoLinkUniversityProtonTherapyProfessionalEducationSignupforouremailEspañolCancerTreatmentProcedures&DiagnosticTestsBloodTests&TumorDiagnosticTestsPa